Lorraine Fitzpatrick, MD

Chief Medical Officer Emeritus, Radius Health, Inc.

Dr. Lorraine A. Fitzpatrick completed her undergraduate education at Wellesley College with honors in Molecular Biology. She graduated from the Pritzker school of Medicine at the University of Chicago where she received an award for her research. She completed her residency training in Internal Medicine at Columbia-Presbyterian Medical Center in New York. Dr. Fitzpatrick trained in Mineral Metabolism and Endocrinology at the National Institute of Diabetes, Digestive, Arthritis and Kidney Disorders at the National Institutes of Health. Dr. Fitzpatrick joined the staff at the Mayo Clinic and rose to the rank of Professor of Medicine. Dr. Fitzpatrick has held many national and international positions. She has published over 250 papers in the field of mineral metabolism. She has received many awards for her research from the ASBMR, The Endocrine Society, the AFCR and was elected to the American Society for Clinical Investigation. She has been an editor or on the editorial boards of multiple publications including Endocrinology, JBMR, Mayo Clinic Proceedings, Bone and Mineral and the Year Book of Endocrinology, to name a few. She has held multiple positions including chair of two study sections at NIH and a member of the Board of Directors for the Office of Women’s Health at NIH.

Dr. Fitzpatrick joined Amgen where she worked on drug development and rose to the title of Global Scientific Director in osteoporosis. Dr. Fitzpatrick then worked in drug development at GlaxoSmithKline as the Medicine Development Leader, leading an international team representing multiple disciplines including clinical development, safety, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. In 2015, Dr. Fitzpatrick joined Radius Health, Inc., as Chief Medical Officer where she leads Clinical Affairs, Medical Affairs and Pharmacovigilance. In 2018, she took the position of Chief Medical Officer Emeritus to focus on abaloparatide and new indications.